MCMedicalCodingSoftware
J9044

J9044: Injection, bortezomib, not otherwise specified, 0.1 mg

HCPCSTerminatedBETOS O1E

J9044 is a HCPCS Level II code for injection, bortezomib, not otherwise specified, 0.1 mg. It belongs to the Drugs Administered Other Than Oral Method section. It was terminated on December 31, 2022 and is not valid on new claims.

This code has been terminated

CMS terminated J9044 on December 31, 2022. It stays in the file as history: a claim you are auditing from before that date may legitimately carry it, but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.

Medicare coverage: Carrier judgment

Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.

From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q4-Oct. This states Medicare’s position on the code, not on your particular claim.

The CMS record for J9044

Long descriptor
Injection, bortezomib, not otherwise specified, 0.1 mg

The official wording. This is what the code means.

Short descriptor
Inj, bortezomib, nos, 0.1 mg

CMS's 28-character form, which is what shows up on a remittance advice.

Added
January 1, 2019

When CMS introduced the code.

Terminated
December 31, 2022

When CMS retired it.

BETOS
O1E

Berenson-Eggers Type of Service: CMS's own analytic grouping.

Pricing indicator
51: Other

Drugs.

Codes adjacent to J9044

HCPCS has no hierarchy: related items simply sit next to each other in the numbering. If J9044 is not quite right, the correct code is very often within a few positions of it.

  • J9036Injection, bendamustine hydrochloride, (belrapzo/bendamustine), 1 mg
  • J9037Injection, belantamab mafodotin-blmf, 0.5 mgterminated
  • J9038Injection, axatilimab-csfr, 0.1 mg
  • J9039Injection, blinatumomab, 1 microgram
  • J9040Injection, bleomycin sulfate, 15 units
  • J9041Injection, bortezomib, 0.1 mg
  • J9042Injection, brentuximab vedotin, 1 mg
  • J9043Injection, cabazitaxel, 1 mg
  • J9045Injection, carboplatin, 50 mg
  • J9046Injection, bortezomib (dr. reddy's), not therapeutically equivalent to j9041, 0.1 mg
  • J9047Injection, carfilzomib, 1 mg
  • J9048Injection, bortezomib (fresenius kabi), not therapeutically equivalent to j9041, 0.1 mg
  • J9049Injection, bortezomib (hospira), not therapeutically equivalent to j9041, 0.1 mg
  • J9050Injection, carmustine, 100 mg
  • J9051Injection, bortezomib (maia), not therapeutically equivalent to j9041, 0.1 mg
  • J9052Injection, carmustine (accord), not therapeutically equivalent to j9050, 100 mg
HCPCS Level II2026Q4-Oct· effective October 1, 2026